Low‐Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION‐INCEPTION, a Randomized, Controlled, Open‐Label Trial
Journal of the American Heart Association · 19.05.2026 · 15 (10)
DOI: 10.1161/jaha.125.043655 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 19.05.2026. Verfasst von Kirk U Knowlton und 11 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Medical Center Heart Institute Murray Utah USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Cholesterol, LDL, RNA, Small Interfering, Dyslipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The low‐density lipoprotein cholesterol (LDL‐C)‐lowering effect of inclisiran, a proprotein convertase subtilisin/kexin type 9‐targeting small interfering RNA, has not been established in patients with recent acute coronary syndrome.
Methods
VICTORION‐INCEPTION, a 330‐day, phase 3b, open‐label, multicenter trial, designed to mimic clinical practice, randomized 400 eligible participants (discharged following acute coronary syndrome ≤5 weeks of screening, with LDL‐C ≥70 mg/dL [or non–high‐density lipoprotein cholesterol ≥100 mg/dL], receiving statin therapy or statin intolerant) 1:1 to inclisiran sodium 300 mg (284 mg inclisiran equivalent; Days 0, 90, 270) + usual care, or usual care (clinician‐directed LDL‐C management). Coprimary end points at Day 330 were LDL‐C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intermountain Medical Center Heart Institute Murray Utah USA.
- Division of Cardiovascular Medicine University of Utah Salt Lake City Utah USA.
- Division of Cardiology UT Southwestern Medical Center Dallas Texas USA.
- Advocate Lutheran General Hospital Park Ridge Illinois USA.
- Wake Forest University School of Medicine Winston-Salem North Carolina USA.
- Novartis Pharmaceuticals Corporation East Hanover New Jersey USA.
ORCID-Profile: Kirk U Knowlton, Ann Marie Navar, Jeffrey L Anderson, Alan S Brown, Joseph B Muhlestein, Samiha Sarwat, Cheryl A Abbas, Mary Ann Ramirez, Cindy L Grines, Nihar R Desai
Zitieren
APA
Knowlton, K. U., Navar, A. M., Anderson, J. L., Brown, A. S., Muhlestein, J. B., Kleeman, K., Sarwat, S., Abbas, C. A., Ramirez, M. A., Grines, C. L., Abo-Auda, W. S., & Desai, N. R. (2026). Low‐Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION‐INCEPTION, a Randomized, Controlled, Open‐Label Trial. Journal of the American Heart Association, 15(10). https://doi.org/10.1161/jaha.125.043655
Vancouver
Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, et al. Low‐Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION‐INCEPTION, a Randomized, Controlled, Open‐Label Trial. Journal of the American Heart Association. 2026;15(10). doi:10.1161/jaha.125.043655
BibTeX
@article{Knowlton2026,
author = {Knowlton, Kirk U and Navar, Ann Marie and Anderson, Jeffrey L and Brown, Alan S and Muhlestein, Joseph B and Kleeman, Kelly and Sarwat, Samiha and Abbas, Cheryl A and Ramirez, Mary Ann and Grines, Cindy L and Abo-Auda, Wael S and Desai, Nihar R},
title = {Low‐Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION‐INCEPTION, a Randomized, Controlled, Open‐Label Trial},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {10},
doi = {10.1161/jaha.125.043655}
}
EUVIMED